Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

ENDRA Life Sciences (NDRA) Gross Margin (2016 - 2018)

ENDRA Life Sciences has reported Gross Margin over the past 3 years, most recently at 100.0% for Q1 2018.

  • Quarterly Gross Margin changed N/A to 100.0% in Q1 2018 from the year-ago period, while the trailing twelve-month figure was 100.0% through Dec 2018, up 4914.0% year-over-year, with the annual reading at 100.0% for FY2018, 4914.0% up from the prior year.
  • Gross Margin was 100.0% for Q1 2018 at ENDRA Life Sciences, up from 54.96% in the prior quarter.
  • Over five years, Gross Margin peaked at 100.0% in Q1 2018 and troughed at 10.98% in Q2 2017.
  • The 3-year median for Gross Margin is 54.96% (2017), against an average of 55.8%.
  • The largest YoY upside for Gross Margin was 71bps in 2017 against a maximum downside of 71bps in 2017.
  • A 3-year view of Gross Margin shows it stood at 54.25% in 2016, then grew by 1bps to 54.96% in 2017, then surged by 82bps to 100.0% in 2018.
  • Per Business Quant, the three most recent readings for NDRA's Gross Margin are 100.0% (Q1 2018), 54.96% (Q4 2017), and 58.79% (Q3 2017).